Description: Parents of children diagnosed with cancer face several unforeseen stressors during all stages of the disease that can impact their mental health. To date, the majority of studies on the effects of childhood cancer on parents’ mental health have been conducted in mothers. This means that we have less understanding of the effects of cancer on fathers’ mental health. This project aims to better understand the impact of pediatric cancer on fathers’ mental health and their use of the psychosocial services offered.

Eligibility:
Fathers residing in the province of Quebec whose child has received a cancer diagnosis, no matter the current cancer phase (recent diagnosis, in treatment, in remission, bereaved, relapse, etc.).

Contact for more information:
cavapapa.hsj@ssss.gouv.qc.ca or the principal investigator, leandra.desjardins.hsj@ssss.gouv.qc.ca.

Description: The goal of this research is to better understand fear of cancer recurrence and how it affects the daily lives of cancer surviors. You  will be asked to complete an online survey (40-55 mins) and 2 daily diaries for 2 weeks.

Eligibility: Adult survivors (18+) of Childhood Cancer

For more information or interest in participating contact: Alex Pizzo, alex.pizzo@mail.concordia.ca

With recent advances in medical treatment, many children diagnosed with a brain tumour are cured. However, survivors often experience learning problems as a result of treatment. Right now, we don’t know a lot about therapies that can help thinking skills and the brain recover after treatment for a brain tumour. Metformin shows great promise in helping the brain recover from damage and improve cognitive function. Drs. Donald Mabbott and Eric Bouffet from The Hospital for Sick Children (SickKids) in Toronto, Ontario, Canada, are leading a group of researchers across Canada and Australia in a double-blind, placebo-controlled trial using cognitive testing and novel brain scanning to see if metformin can improve thinking skills and help the brain grow in pediatric brain tumour survivors.

Eligibility: Your child is eligible to participate in the study if they:

• Have finished primary therapy (minimum 3 weeks after end of therapy) for a brain tumour such as medulloblastoma, ependymoma, craniopharyngioma, germ cell tumour, or other brain tumour treated with cranial radiation OR relapsed ependymoma treated with cranial radiation
• Are between 7 and 21 years of age
• Have English as their native language or have had at least two years of schooling in English
• Are able to swallow tablets either whole or crushed or via feeding tube
• Meet criteria for adequate organ function requirements

Your child is not eligible to participate in the study if they:

• Have an IQ of less than 60 on screening test
• Have a known hypersensitivity to metformin
• Have unstable and/or insulin-dependent (Type 1) diabetes
• Have a history of renal (kidney) disease or malfunction, or congestive heart failure
• Are taking part in another intervention study
• Are currently using metformin
• Are on palliative care

Contact: Email metmedcan.main@sickkids.ca if you are interested in participating and/or would like more information about the study.

We hope to enroll 2000 people to get a complete picture of what it means to have cancer as a young adult right now. The information you provide will be used to increase awareness and develop programs to address the issues that Young Adults with cancer feel are most important. People living in Canada who are over the age of 18 and were diagnosed with any type of cancer before the age of 40. You will complete an online survey once a year for up to five years. Each survey will take approximately 30-45 minutes to complete.

All you have to do is complete the following link:

complete study

Once we confirm your eligibility, you will receive an email with a unique link to complete the survey.

For more information – research@youngadultcancer.ca

The study, conducted by the Injury Prevention Research Office and St. Michael’s Hospital in Toronto, Canada aims to measure the effect of visual symptoms on the quality of life in patients with pituitary tumors. Visual symptoms are one of the most common effects of large pituitary tumors. This study is aimed to develop a tool to better measure the effect of these visual symptoms on a pituitary tumor patient’s ability to function in daily life. Anyone who is currently/or has ever been diagnosed with a pituitary tumor. If you are interested in participating in the study by completing the survey, click here. This survey should take about 45 minutes to complete.

If you have any other questions, please feel free to contact us at: injuryprevention@smh.ca

The purpose of this study is to discover why some people develop LGG while other people do not. We also hope to learn more about the effect of this diagnosis and the associated treatments on daily life including the ability to work, drive, sleep, exercise, or take care of oneself and/or family. Any person over the age of 20 years with an initial diagnosis of LGG. Postmortem tissue samples and pathology reports may also be eligible for inclusion in the study. Please email for more information.

For more information: email the study at: glioma@yale.edu